Cardiomyopathy Innovation Patient Care 
DAIC
MARCH 6, 2024
Food and Drug Administration’s ( FDA ) Breakthrough Device Designation for their ECGvision-TTR Technology for early detection of ATTR-Cardiomyopathy. Food and Drug Administration’s (FDA) Breakthrough Devices Program , which provides patients with timely access to innovative medical devices.
DAIC
FEBRUARY 18, 2025
11, 2025 UltraSight, a company committed to enhancing the efficiency and productivity of cardiac ultrasound,recentlyannounced support from Bristol Myers Squibb (BMS) for a study that aims to improve access to echocardiographic assessments for patients with obstructive hypertrophic cardiomyopathy (oHCM).
DAIC
FEBRUARY 29, 2024
24 and how those may impact clinical practice and patient care in this deep dive clinical trial session. 12:15 p.m. ET Murphy Ballroom 4 ACC.24 24 planners note that attendees can gain insights from key clinical trials presented at ACC.24 More information: www.acc.org If you enjoy this content, please share it with a colleague
Wellnest
JUNE 19, 2023
By harnessing the power of the latest technology, healthcare providers can enhance diagnostics, treatment planning, and patient care. With the continued evolution of AI, it is now being introduced in cardiac healthcare, promising opportunities for innovation and advancements in cardiovascular medicine. For instance: 1.
Cardiometabolic Health Congress
JANUARY 2, 2025
November 2024 Approvals Acoramidis Approval Date: November 22, 2024 Indication: Approved for adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and severe cardiac condition. By prioritizing patient-centric innovation, these advancements emphasize the importance of addressing unmet medical needs.
Expert insights. Personalized for you.
105 
Let's personalize your content